

Daily tadalafil tablets Position Statement

Tadalafil 5mg tablet daily is recommended post nerve sparing radical prostatectomy (3-month course supplied by the hospital, not for prescribing in primary care).

Tadalafil 2.5mg tablet is not recommended for use in NCL

For PDE5i use in erectile dysfunction, please see the [NCL primary care pathway](#)

Erectile dysfunction (ED)

- Primary care clinicians can access the ED pathway via the NCL GP website ([link here](#))

Nerve-sparing radical prostatectomy (NSRP)

- Tadalafil 5mg tablet daily is recommended post nerve-sparing radical prostatectomy (NSRP); maximum treatment duration is 3 months^a with the full supply prescribed by the hospital specialist.
- Tadalafil 2.5mg tablet daily is not recommended owing to high cost.
- Patients prescribed any PDE5i in primary care for NSRP should be referred back to their urologist to review need for ongoing prescribing.

Benign prostatic hyperplasia (BPH)

- Tadalafil tablet daily (5mg or 2.5mg) is not recommended for benign prostatic hyperplasia prescribing^b therefore an alternative treatment option should be prescribed by GP or specialist.
- [NICE CG97](#) (Lower urinary tract symptoms in men: management) recommends that prescribers do **not** offer PDE5 inhibitors solely for the purpose of treating lower urinary tract symptoms in men, except as part of a randomised controlled trial. This is due to a lack of evidence of its efficacy in the treatment of BPH in the absence of ED. [1]
- Patients prescribed tadalafil tablet daily for BPH should be referred back to the specialist for review and change of treatment.

^a Discussed at JFC in [November 2014](#), [January 2015](#), and [May 2021](#)

^b JFC has not reviewed tadalafil daily for this indication

References

[1] National Institute of Health and Care Excellence. CG97. Lower urinary tract symptoms in men: management. Last updated: June 2015. <https://www.nice.org.uk/guidance/cg97> [Accessed: 27/08/2021]

Groups / Individuals who have overseen the development of this guidance:	JFC Support Pharmacists Ms D Joshi (UCLH) Prof D Ralph (UCLH)
Groups which were consulted and have given approval:	NCL Joint Formulary Committee
File name:	7_daily_tadalafil_position_statement.pdf
Version number:	2.0
Available on:	NCL MON website
Disseminated to:	All Trusts and CCGs in NCL
Equality impact assessment:	Low
NCL Joint Formulary Committee Approval date:	April 2022
Review date:	April 2025